Cargando…

Treating allergic conjunctivitis: A once-daily medication that provides 24-hour symptom relief

BACKGROUND: Allergic conjunctivitis (AC) is a common ocular inflammatory manifestation of allergen exposure in sensitized individuals. Signs and symptoms of AC can decrease quality of life, interfere with productivity, and lead to considerable economic burden. Consistent suppression of conjunctival...

Descripción completa

Detalles Bibliográficos
Autores principales:	Carr, Warner, Schaeffer, Jack, Donnenfeld, Eric
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	OceanSide Publications, Inc. 2016
Materias:	Articles
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5010431/ https://www.ncbi.nlm.nih.gov/pubmed/27466061 http://dx.doi.org/10.2500/ar.2016.7.0158

Ejemplares similares

24-hour efficacy of once-daily desloratadine therapy in patients with seasonal allergic rhinitis [ISRCTN32042139]
por: Salmun, Luis M, et al.
Publicado: (2002)

Bepotastine besilate ophthalmic solution 1.5% for alleviating nasal symptoms in patients with allergic conjunctivitis
por: Cavet, Megan E, et al.
Publicado: (2018)

Allergic conjunctivitis
por: Rathi, Varsha M, et al.
Publicado: (2017)

Allergic Conjunctivitis in Patients with Respiratory Allergic Symptoms; a Retrospective Study in Greece
por: MICHAILOPOULOS, Pavlos, et al.
Publicado: (2017)

Once daily levocetirizine for the treatment of allergic rhinitis and chronic idiopathic urticaria
por: Nettis, E, et al.
Publicado: (2008)

Allergic conjunctivitis in Asia
por: Thong, Bernard Yu-Hor
Publicado: (2017)

24-Hour Serial Spirometric Assessment of Once-Daily Fluticasone Furoate/Umeclidinium/Vilanterol Versus Twice-Daily Budesonide/Formoterol in Patients with COPD: Analysis of the FULFIL Study
por: Lipson, David A., et al.
Publicado: (2020)

Recognition of allergic conjunctivitis in patients with allergic rhinitis
por: Williams, Daniel C, et al.
Publicado: (2013)

Allergic conjunctivitis in Jos-Nigeria
por: Malu, Keziah N.
Publicado: (2014)

Current Knowledge in Allergic Conjunctivitis
por: Villegas, Beatriz Vidal, et al.
Publicado: (2021)

Therapeutic Targets in Allergic Conjunctivitis
por: Labib, Bisant A., et al.
Publicado: (2022)

The 24-Hour Cardiac Autonomic Activity in Patients With Allergic Rhinitis
por: Won, Jun Yeon, et al.
Publicado: (2023)

Evaluation of nephrotoxicity and ototoxicity following amikacin administration once daily or every 48 hours in neonates
por: Endo, Aiju, et al.
Publicado: (2022)

Relationship between allergic rhinitis and allergic conjunctivitis (allergic rhinoconjunctivitis) - review
por: Iordache, Andreea, et al.
Publicado: (2022)

Safety of cetirizine ophthalmic solution 0.24% for the treatment of allergic conjunctivitis in adult and pediatric subjects
por: Malhotra, Ranjan P, et al.
Publicado: (2019)

Aqueous-Deficient Dry Eye Exacerbates Signs and Symptoms of Allergic Conjunctivitis in Mice
por: Kishimoto, Tatsuma, et al.
Publicado: (2022)

359 Prevalence of Allergic Conjunctivitis in Childhood
por: Geraldini, Marcos, et al.
Publicado: (2012)

A contemporary look at allergic conjunctivitis
por: Dupuis, Pascale, et al.
Publicado: (2020)

Corneal biomechanical changes in allergic conjunctivitis
por: Wang, Qian, et al.
Publicado: (2021)

The anatomical and functional relationship between allergic conjunctivitis and allergic rhinitis
por: Hom, Milton M., et al.
Publicado: (2013)

Model for Studying Anti- Allergic Drugs for Allergic Conjunctivitis in Animals
por: Nakazawa, Yosuke, et al.
Publicado: (2017)

Management of allergic conjunctivitis: an evaluation of the perceived comfort and therapeutic efficacy of olopatadine 0.2% and azelastine 0.05% from two prospective studies
por: Epstein, Arthur B, et al.
Publicado: (2009)

Evaluation of alcaftadine 0.25% ophthalmic solution in acute allergic conjunctivitis at 15 minutes and 16 hours after instillation versus placebo and olopatadine 0.1%
por: Greiner, Jack V, et al.
Publicado: (2011)

Blocking Th2 Signaling Pathway Alleviates the Clinical Symptoms and Inflammation in Allergic Conjunctivitis
por: Tao, Zhiyan, et al.
Publicado: (2023)

Once-daily dosing of gentamicin.
por: Soper, D E
Publicado: (1998)

Efficacy and Safety of Once Daily Fluticasone Furoate Nasal Spray for Treatment of Irritant (Non-allergic) Rhinitis
por: Tantilipikorn, Pongsakorn, et al.
Publicado: (2010)

Curcumin suppresses ovalbumin-induced allergic conjunctivitis
por: Chung, So-Hyang, et al.
Publicado: (2012)

Allergic conjunctivitis: a comprehensive review of the literature
por: La Rosa, Mario, et al.
Publicado: (2013)

A survey of allergic conjunctivitis in children in China
por: Gao, Xu, et al.
Publicado: (2022)

Oleanolic Acid Controls Allergic and Inflammatory Responses in Experimental Allergic Conjunctivitis
por: Córdova, Claudia, et al.
Publicado: (2014)

Sams teach yourself Windows PowerShell in 24 hours
por: Warner, Timothy L
Publicado: (2015)

Sams teach yourself Scratch 2.0 in 24 hours
por: Warner, Timothy L
Publicado: (2014)

Ocular Itch Relief with Alcaftadine 0.25% Versus Olopatadine 0.2% in Allergic Conjunctivitis: Pooled Analysis of Two Multicenter Randomized Clinical Trials
por: McLaurin, Eugene B., et al.
Publicado: (2014)

ONCE DAILY RISPERIDONE IN TREATMENT OF SCHIZOPHRENIA
por: Agarwal, Vivek, et al.
Publicado: (2001)

Treatment of allergic conjunctivitis with olopatadine hydrochloride eye drops
por: Uchio, Eiichi
Publicado: (2008)

Allergic conjunctivitis and the most common allergens in Northern Greece
por: Almaliotis, Diamantis, et al.
Publicado: (2013)

Therapeutic Targeting of Eosinophil Adhesion and Accumulation in Allergic Conjunctivitis
por: Baiula, Monica, et al.
Publicado: (2012)

Dry Eye Syndrome and Allergic Conjunctivitis in the Pediatric Population
por: Akil, Handan, et al.
Publicado: (2015)

Validation of the DECA criteria for allergic conjunctivitis severity and control
por: Sánchez-Hernández, M. Cesárea, et al.
Publicado: (2020)

Astigmatism Associated with Allergic Conjunctivitis in Urban School Children
por: Kim, Yangho, et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_ld57scnua7mffkuaasgcbs3q6n